Research Study for Chronic Myeloid Leukemia (CML)


If you have been diagnosed with chronic phase chronic myeloid leukemia (CML) within the past 6-months, you may want to consider participating in the BFORE clinical research study. The BFORE study will evaluate a recently approved marketed medication for CML verses the current standard of care treatment for CML.

See if you may qualify for the BFORE study

The BFORE study is being conducted to find out if bosutinib, a medication regularly used as a second or third treatment option for CML, works well as a first treatment option for patients recently diagnosed with CML. Bosutinib has shown promise in recent clinical trials, and has been successful in treating patients whose leukemia has not responded to other types of medication.

You may be eligible to participate in the study if you:

  • Are at least 18 years old
  • Have been diagnosed with chronic phase CML within the past 6 months
  • Have not received treatment for CML other than with drugs used to control blood counts (for example, hydroxyurea or anagrelide)

Study participation will last approximately 5 years and includes visits to the research center for study-related tests and procedures to closely monitor your progress. The study medication will be provided for the duration of participation.

To learn more or to see if you may qualify for the study, visit www.BFOREstudy.com.

Thank you for your consideration. The results of the BFORE study may help improve the standard of care for CML patients in the future.